Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

NCR graphs - Age specific incidence rates

- All cancer age-specific incidence rates, including non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, including non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- Oesophagus cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Oesophagus cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Estomac cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Estomac cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Colo-rectal cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Colo-rectal cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Liver cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Liver cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Pancreas cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Pancreas cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Larynx cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Larynx cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Trachea-bronchus-lung cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Trachea-bronchus-lung cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bone cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bone cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Melanoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Melanoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-melanoma skin cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-melanoma skin cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Breast cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Breast cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Col uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Corpus uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Ovary cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Prostate cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Testis cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015

- Kidney cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Kidney cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bladder cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bladder cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Brain and central nervous system cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Brain and central nervous system cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Thyroid cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Thyroid cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Hodgkin's lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Hodgkin's lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-Hodgkin lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-Hodgkin lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Multiple Myeloma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Multiple Myeloma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Lymphoid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Lymphoid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Myeloid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Myeloid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
 
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
J07AH08 MENACTRA MENINGOCOCCAL POLYSACCHARIDE DIPHTERIA TOXOID CONJUGATE VACCINE B Meningococcal Polysaccharides (serogroups A, C, Y and W-135) - 4mcg/0.5ml each, Diphteria Toxoid Protein - 48mcg/0.5ml Injectable solution 6,144,048 L.L
L03AX16 MOZOBIL B Plerixafor - 20mg/ml 20mg/ml Injectable solution 413,801,327 L.L
L04AA06 MYFORTIC B Mycophenolic acid (sodium) - 360mg 360mg Tablet, gastroresistant 19,462,901 L.L
J07BD52 M-M-R II (MEASLES, MUMPS AND RUBELLA VIRUS VACCINE LIVE) B Rubella virus live attenuated - , Mumps virus live attenuated - , Measles virus live attenuated - Injectable solution+diluent 12,924,401 L.L
A06AD65 MOVICOL B Potassium chloride - 0.0466g, Sodium chloride - 0.3507g, Sodium bicarbonate - 0.1785g, Macrogol 3350 - 13.125g Powder for solution 853,340 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 15,102,158 L.L
A06AD65 MOVICOL PEDIATRIC PLAIN B Potassium chloride - 23.3mg, Sodium chloride - 175.4mg, Sodium bicarbonate - 89.3mg, Macrogol 3350 - 6.563g Powder for solution 624,887 L.L
L04AA42 MAYZENT B Siponimod - 0.25mg 0.25mg Tablet, film coated 124,258,444 L.L
L04AA42 MAYZENT B Siponimod - 2mg 2mg Tablet, film coated 124,258,444 L.L
G03GA02 MENO-CLAIR HP-HMG BioHuman Human Menopausal Gonadotrophin, Highly purified - 75IU 75IU Injectable powder for solution + solution 1,045,509 L.L
G03GA02 MENOPUR BioHuman Menotropin - 75IU 75IU Injectable concentrated powder for solution+diluent 16,864,077 L.L
G03GA02 MERIONAL HG BioHuman Menotropin - 75IU 75IU Injectable powder + solvent 24,771,315 L.L
G03GA02 MENOPUR BioHuman Menotropin - 1,200IU 1,200IU Injectable powder for solution+diluent 27,815,659 L.L
G03GA02 MENOPUR BioHuman Menotropin - 600IU 600IU Injectable powder for solution+diluent 13,907,829 L.L
G03GA02 MENO-CLAIR HP-HMG BioHuman Human Menopausal Gonadotrophin, Highly purified - 150IU 150IU Injectable powder for solution + solution 2,005,013 L.L
G03GA02 MERIONAL HG BioHuman Menotropin - 150IU 150IU Injectable powder + solvent 41,777,992 L.L
G03GA02 MERIONAL HG BioHuman Menotropin - 900IU 900IU Injectable powder + solvent 25,830,983 L.L
L01FA01 MABIXEN 100 BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 22,183,393 L.L
L01FA01 MABIXEN 100 BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 11,091,696 L.L
L01FA01 MABTHERA BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrated solution 35,722,424 L.L
L01FA01 MABIXEN 500 BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 136,761,210 L.L
L01FA01 MABIXEN 500 BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 74,718,320 L.L
L01FA01 MABTHERA BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrated solution 80,211,932 L.L
L01FD01 MABTIN 440 BioTech Trastuzumab (r-DNA origin) - 440mg 440mg Injectable powder for solution 70,042,700 L.L
L01FG01 MVASI BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 58,035,926 L.L
L01FG01 MVASI BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable concentrate for solution 17,173,671 L.L
L01FX02 MYLOTARG BioTech Gemtuzumab Ozogamicin - 4.5mg 4.5mg Injectable powder 748,160,090 L.L
A10AD01 MIXTARD 30 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
A10AD01 MIXTARD 30 BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 752,552 L.L
A16AB07 MYOZYME BioTech Alglucosidase alfa, recombinant human acid - 50mg 50mg Injectable powder for concentrate for solution 54,382,728 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025